Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients
Phase 3
Completed
- Conditions
- Health Condition 1: null- Fibromyalgia
- Registration Number
- CTRI/2011/09/002015
- Lead Sponsor
- Pfizer Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 290
Inclusion Criteria
Patients must have fibromyalgia.
Exclusion Criteria
Patients with other painful conditions cannot participate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to loss of therapeutic response based on pain response relative to baseline or patient discontinuationTimepoint: 19 weeks
- Secondary Outcome Measures
Name Time Method